Trial Profile
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2018
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Regorafenib
- Indications Colorectal cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Incyte Corporation
- 31 Aug 2018 Biomarkers information updated
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium
- 18 Jan 2017 This trial has been completed in Spain (end date: 17 Dec 2016).